Moderna and Merck Report Positive Phase 3 Results for Personalized Cancer Therapy
· Texas Border Business
Moderna and Merck have announced promising Phase 3 results for their personalized mRNA cancer therapy, intismeran autogene, when used alongside Keytruda (pembrolizumab) for patients with high-risk melanoma. This treatment aims to enhance the immune system's ability to identify and combat cancer cells tailored to individual tumor characteristics. Moderna's CEO, Stéphane Bancel, indicated that they are progressing towards regulatory discussions and preparing to share detailed findings with the medical community. The study showed a significant improvement in patients with completely resected Stage IIB-IV melanoma compared to those receiving only Keytruda, although the FDA has yet to approve the therapy.
AI summary · Source: Texas Border Business →
